MT3
Advancing radiosensitizer technology to treat animal tumors with innovative therapeutic solutions.
Advancing radiosensitizer technology to treat animal tumors with innovative therapeutic solutions.
MT3 is a health care startup that is advancing radiosensitizer technology to treat animal tumors with innovative therapeutic solutions. Founded in 2018, the company focuses on providing treatment to animals suffering from tumors by offering therapeutic agents, treating various forms of tumors, and providing anti-tumor treatment. In their latest milestone, MT3 received a Seed Round investment on 19 November 2020 from investors including REVIC and Gungin Consulting. This investment is a testament to the potential of MT3's pioneering technology in the field of animal tumor treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 2 |
|
19 Nov 2020 |
No recent news or press coverage available for MT3.
We care about your data, and we'd love to use cookies make your experience better.